Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARTERIAL VASCULAR ENGINEERING -- Ignore unavailable to you. Want to Upgrade?

To: B4TheBell who wrote (323)	12/30/1997 3:18:00 PM
From: D.E. Shetland	Respond to of 339

I see a UK company (Biocompatibles) just got CE Mark Approval to sell stents in Europe and that the re-stenosis rate exhibited in the trials was around 5%. I believe the design and a coating applied to it account for the high success rate. That's quite a bit below the other stent's on the market. Anyone have an idea what such a low number might do to market share's in Europe & (I guess) eventually, US?

To: B4TheBell who wrote (323)	1/6/1998 1:43:00 PM
From: Jeff Gurian	Read Replies (1) \| Respond to of 339

I heard the third week in Jan. for Guidant's earnings, but Im not positive on that information. Yeah, there should be a boost by association, AVE stock went up more then Guidant when Guidant finally got their FDA approval. As those analysts noted yesterday when downgrading AVE, though, Im not sure how much money they can make after the next 2 to 4 quarters. Keeping growth rates will be very difficult. If you happen to come across the Guidant earnings date I would appreciate if you would let me know. I'll try and do likewise.